Instructions for Noopept (N-Phenylacetyl-L-prolylglycine ethyl ester)
Noopept is a drug with nootropic and neuroprotective properties. Improves learning ability, memory, affecting all phases of memorization: initial information processing, consolidation, retrieval. It prevents the development of amnesia caused by electroshock, blockage of central cholinergic structures, glutamatergic receptor systems, elimination of the paradoxical phase of sleep (in experiments in rats).
The neuroprotective (protective) effect of Noopept is manifested in increasing the resistance of brain tissue to damage (injury, hypoxia, electroconvulsive, toxic action) and in weakening the degree of damage to brain neurons. The preparation reduces the prevalence of the lesion site on the thrombotic model of stroke and prevents the death of neurons in the culture of the cerebral cortex and cerebellum tissue, which were exposed to neurotoxic concentrations of glutamate, free radical oxygen (on experimental models).
Noopept has antioxidant effect, antagonistic effect on the effect of excess calcium content, improves rheological properties of blood, exhibits antiaggregant, fibrinolytic and anticoagulant properties.
The nootropic effect of the preparation is associated with the formation of cycloprolylglycine, which is similar in structure to endogenous cyclic dipeptide exhibiting antiamnesic activity, and also with the presence of cholinpositive action.
Noopept increases the amplitude of the transcallosic response by facilitating associative connections between brain hemispheres at the level of cortical structures.
Noopept promotes memory and other cognitive functions impaired by damaging effects such as brain injury, local or common ischemia, and prenatal damage (alcohol, hypoxia).
The therapeutic effect of the drug in patients with organic disorders of the CNS manifests itself starting from the 5-7th day of treatment. At first, anxiolytic and light stimulating effects are realized in the spectrum of Noopept activity, said effects manifesting in the reduction or disappearance of anxiety conditions, increased irritability, affective lability and sleep disturbances. After 14-20 days of therapy, the drug has a positive effect on cognitive functions, attention and memory parameters.
Noopept has a vegetative effect, helps to reduce headache, orthostatic disorders, tachycardia.
Noopept is not smoked in the body, does not cause drug dependence. Withdrawal symptoms are not noted.
Noopept does not damage internal organs, does not lead to changes in hematological and biochemical parameters; it has no immunotoxic, teratogenic or mutagenic effects.
Noopept, absorbed into the gastrointestinal tract, enters the systemic bloodstream in an unaltered way, penetrates through the HEV, and is detected in brain tissue at a higher concentration than in blood plasma. The average time to reach the maximum concentration in the blood serum is 15 minutes. The half-life of the blood plasma is 23 minutes. The drug is partially preserved intact and partially metabolized to form phenylacetic acid, phenylacetylproline, and cycloprolylglycine. It has a relatively high bioavailability of 99.7%.
Impaired memory, attention, perception and appreciation of reality, including in older patients;
consequences of traumatic brain injury (impaired memory of traumatic genesis);
cerebrovascular insufficiency, including after impaired cerebral circulation with signs of reduced intelligence, emotional and labile disorders.
The tablets are prescribed to adults inside after eating. The initial dose of the drug is 20 mg in 2 doses (morning and afternoon). If the therapy is not effective enough and the dose is tolerable enough, the dose is increased to 30 mg, spread over 3 doses during the day. Do not take the drug after 18:00.
Duration of treatment 1,5-3 months If necessary, repeat the course of therapy after 1 month.
Period of pregnancy and breastfeeding, age up to 18 years (data on use in this group of patients is not available). Increased sensitivity to drug components. Severe liver and kidney dysfunction.
Side effects Noopept:
Allergic reactions are possible. In patients with AG (Art. II-III), an increase in AD may be noted against the background of the drug intake.
There is no data on safe use during pregnancy and breastfeeding.
Data on use in children are not available.
Features of application.
The dose increase (up to 30 mg/day), long-term use with other drugs should be carried out under the supervision of a doctor. The patient should be warned that if there are adverse reactions or the condition deteriorates, he should see a doctor.
The ability to influence reaction rates when driving or working with other mechanisms is not known.
Noopept has not been shown to interact with alcohol, sleeping pills, antihypertensive and psychostimulant drugs.
No cases were reported.
Store in a dry, light-proof place at a temperature not exceeding 25 °C.